


WCLC 2016 Industry Satellite Symposium

Harnessing the power of immunotherapy and targeted therapy: translating evidence into practice

Invitation

Tuesday 6 December 2016
17.45–19.15

Hall C2
Messe Wien Exhibition & Congress Center
Vienna, Austria



This presentation was approved by the IASLC 17th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 17th World Conference on Lung Cancer. This presentation is not sponsored or endorsed by IASLC.


This symposium is not intended for physicians practising in the USA
NP/ONCO/1611/0053

Tuesday 6 December 2016 | 17.45–19.15 | Hall C2

Harnessing the power of immunotherapy and targeted therapy: translating evidence into practice

As we will witness again here in Vienna, the treatment of non-small cell lung cancer (NSCLC) has entered another exciting period of intense development. The advances made in recent years have been astounding, and rapidly translating the benefits observed in medical research to daily clinical practice has become an important challenge for the whole oncology community. In this symposium, highly respected experts in NSCLC care will discuss the latest data on targeted therapy and immunotherapy, and consider how these lessons can be applied to benefit individual patients. We hope that you will be able to attend and actively participate in this engaging session, and look forward to welcoming you there.

Venue Floorplan



Programme

- 17.45 Introduction**
Dr David Spiegel (USA) [Chair]
- 17.50 ALK: the power of targeted therapy**
Prof Frank Griesinger (Germany)
- 18.15 Latest developments in the treatment of EGFR Mut+ NSCLC**
Dr Federico Cappuzzo (Italy)
- 18.30 The power of the immune system: immunotherapy in practice**
Dr Achim Rittmeyer (Germany)
- 19.10 Summary and Close**
Dr David Spiegel